Bill
Bill > A4642
NJ A4642
NJ A4642Clarifies that testosterone therapy is covered treatment under the "New Jersey Menopause Coverage Act."
summary
Introduced
03/10/2026
03/10/2026
In Committee
03/10/2026
03/10/2026
Crossed Over
Passed
Dead
Introduced Session
2026-2027 Regular Session
Bill Summary
This bill clarifies that testosterone therapy is a covered treatment under the "New Jersey Menopause Coverage Act." Under the bill, health insurance carriers (including insurance companies, hospital service corporations, medical service corporations, health service corporations, and health maintenance organizations authorized to issue health benefits plans in New Jersey, entities contracted to administer health benefits in connection with the State Health Benefits Program and School Employees' Health Benefits Program, and the New Jersey FamilyCare Program) will be required to cover, as part of their coverage of medically necessary perimenopause and menopause treatments under the "New Jersey Menopause Coverage Act," testosterone therapy. The bill also requires that benefits for the prescribed testosterone therapy be provided to the same extent as for any other hormonal treatment under the bill, and stipulates that prescribed testosterone therapy will not be denied by a carrier if the therapy is not indicated by the federal Food and Drug Administration to be approved for perimenopause or menopause.
AI Summary
This bill clarifies that testosterone therapy is a covered treatment under New Jersey's laws mandating coverage for medically necessary perimenopause and menopause treatments, ensuring that health insurance carriers, including companies, hospital service corporations, medical service corporations, health service corporations, health maintenance organizations, and state-administered health programs, must cover testosterone therapy for these conditions. The bill specifies that benefits for prescribed testosterone therapy should be provided to the same extent as other hormonal treatments and prohibits carriers from denying coverage if the therapy is not explicitly approved by the federal Food and Drug Administration (FDA) for perimenopause or menopause, recognizing that such therapies can still be medically necessary. This change aims to ensure broader access to treatment options for women experiencing symptoms related to perimenopause and menopause.
Committee Categories
Business and Industry
Sponsors (2)
Last Action
Introduced, Referred to Assembly Financial Institutions and Insurance Committee (on 03/10/2026)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.njleg.state.nj.us/bill-search/2026/A4642 |
| BillText | https://pub.njleg.gov/Bills/2026/A5000/4642_I1.HTM |
Loading...